News & Press Releases
Filter by:
Member Rachel Alexander was quoted in a Bloomberg Law article examining how recent federal appellate court rulings are putting state pharmacy laws under increased scrutiny, particularly “any willing pharmacy” requirements affecting pharmacy benefit managers and ERISA regulated health plans.
Mintz Represents AI-Powered Warehouse Robotics Innovator SIMPL Automation in Its Sale to The Home Depot
April 20, 2026
Mintz represented SIMPL Automation, a Massachusetts–based warehouse automation company that develops modular, AI‑powered robotics and automated storage and retrieval systems, in its sale to The Home Depot, the world’s largest home improvement retailer. The transaction enables The Home Depot to accelerate supply chain automation while enhancing speed, efficiency, and delivery capabilities for in-demand products across its distribution network.
Mintz Advising on $350 Million Private Placement Concurrent with Obsidian Therapeutics’ and Galera Therapeutics’ Merger Transaction
April 17, 2026
Mintz is advising the placement agents in connection with the $350 million private placement that is expected to close immediately prior to the completion of the merger transaction between Obsidian Therapeutics, Inc. and Galera Therapeutics, Inc.
Mintz Advises on ImageneBio’s $30 Million Private Placement
April 15, 2026
Mintz advised the placement agent in connection with ImageneBio’s $30 million private placement of pre-funded warrants.
Why Data Centers Are Turning to Behind-the-Meter Power
April 15, 2026
Steven Shparber, Co-chair of Mintz’s Digital Infrastructure Practice, recently spoke with Data Center Knowledge about the growing use of behind-the-meter power by data center operators as they face grid delays and rising AI-driven demand.
Mintz advised the placement agent in connection with SCYNEXIS’ up to $92.2 million private placement. The private placement included upfront gross proceeds of approximately $40.0 million in common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants, and up to an additional $52.2 million in gross proceeds if the common warrants are exercised for cash, subject to stockholder approval to increase the number of authorized shares of common stock.

